ConductScience.org, home

Paper25753636

Pharmacodynamics of isavuconazole in an Aspergillus fumigatus mouse infection model.

Seyedmousavi S and 5 others. Antimicrob Agents Chemother, 2015. Cited by 61 papers, by iCite.

Cite this record

ConductScience Library. Pharmacodynamics of isavuconazole in an Aspergillus fumigatus mouse infection model. Papers, record 25753636. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/25753636

Download JSON
Sources
11 sources
Release
papers-2026-11-12-0.1.0

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
Pharmacodynamics of isavuconazole in an Aspergillus fumigatus mouse infection model.
PubMed
Journal
Antimicrob Agents Chemother
PubMed
Year
2015
PubMed
Publication types
Journal Article, Research Support, Non-U.S. Gov't
PubMed
Citations, by iCite
61
iCite
Relative citation ratio, by iCite
2.84
iCite
Revised in PubMed
2018-11-13
PubMed

Authors6

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1Seyedmousavi SSeyedmojtabahttps://orcid.org/0000-0002-6194-7447
2Brüggemann RJRoger J M
3Meis JFJacques F
4Melchers WJWillem J G
5Verweij PEPaul E
6Mouton JWJohan Whttps://orcid.org/0000-0001-6736-4149

Source PubMed

Download CSV of authors

Topics8

NLM's MeSH indexing of the paper, its major topics first.

MeSH termMajor
Aspergillus fumigatusMajor topic
NitrilesMajor topic
PyridinesMajor topic
TriazolesMajor topic
Animals
Aspergillosis
Female
Mice

Source PubMed

Download CSV of topics

References65

The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.

OrderPMIDTitleJournalYearIn PapersSource
119101840Multiple-azole-resistant Aspergillus fumigatus osteomyelitis in a patient with chronic granulomatous disease successfully treated with long-term oral posaconazole and surgery.Med Mycol2009https://conductscience.org/library/papers/19101840PubMed
219624922Frequency and evolution of Azole resistance in Aspergillus fumigatus associated with treatment failure.Emerg Infect Dis2009https://conductscience.org/library/papers/19624922PubMed
318462102
Revised definitions of invasive fungal disease from the European Organization for Research and Treatment of Cancer/Invasive Fungal Infections Cooperative Group and the National Institute of Allergy and Infectious Diseases Mycoses Study Group (EORTC/MSG) Consensus Group.
Clin Infect Dis2008https://conductscience.org/library/papers/18462102PubMed
423129729Efficacy and pharmacodynamics of voriconazole combined with anidulafungin in azole-resistant invasive aspergillosis.J Antimicrob Chemother2013https://conductscience.org/library/papers/23129729PubMed
512501236Multidrug resistance in Aspergillus fumigatus.N Engl J Med2002https://conductscience.org/library/papers/12501236PubMed
623114773Pharmacodynamics of anidulafungin against clinical Aspergillus fumigatus isolates in a nonneutropenic murine model of disseminated aspergillosis.Antimicrob Agents Chemother2013https://conductscience.org/library/papers/23114773PubMed
717071636Comparative in vivo activity of BAL4815, the active component of the prodrug BAL8557, in a neutropenic murine model of disseminated Aspergillus flavus.J Antimicrob Chemother2006https://conductscience.org/library/papers/17071636PubMed
818177225Treatment of aspergillosis: clinical practice guidelines of the Infectious Diseases Society of America.Clin Infect Dis2008https://conductscience.org/library/papers/18177225PubMed
921895037Penetration of anti-infective agents into pulmonary epithelial lining fluid: focus on antibacterial agents.Clin Pharmacokinet2011https://conductscience.org/library/papers/21895037PubMed
1016284102In vitro activity of a new triazole BAL4815, the active component of BAL8557 (the water-soluble prodrug), against Aspergillus spp.J Antimicrob Chemother2006https://conductscience.org/library/papers/16284102PubMed
1123697829Azole-resistant Aspergillus fumigatus, Iran.Emerg Infect Dis2013https://conductscience.org/library/papers/23697829PubMed
1218212101In vitro antifungal activities of isavuconazole (BAL4815), voriconazole, and fluconazole against 1,007 isolates of zygomycete, Candida, Aspergillus, Fusarium, and Scedosporium species.Antimicrob Agents Chemother2008https://conductscience.org/library/papers/18212101PubMed
1312512185Aspergillosis. Pathogenesis, clinical manifestations, and therapy.Infect Dis Clin North Am2002https://conductscience.org/library/papers/12512185PubMed
1423183435In vitro interaction of voriconazole and anidulafungin against triazole-resistant Aspergillus fumigatus.Antimicrob Agents Chemother2013https://conductscience.org/library/papers/23183435PubMed
1522530880Evaluation of the pharmacokinetics and clinical utility of isavuconazole for treatment of invasive fungal infections.Expert Opin Drug Metab Toxicol2012https://conductscience.org/library/papers/22530880PubMed
1624566183Intrapulmonary posaconazole penetration at the infection site in an immunosuppressed murine model of invasive pulmonary aspergillosis receiving oral prophylactic regimens.Antimicrob Agents Chemother2014https://conductscience.org/library/papers/24566183PubMed
1716377699Multiple-dose pharmacokinetics and safety of the new antifungal triazole BAL4815 after intravenous infusion and oral administration of its prodrug, BAL8557, in healthy volunteers.Antimicrob Agents Chemother2006https://conductscience.org/library/papers/16377699PubMed
1818326856Activity of BAL 4815 against filamentous fungi.J Antimicrob Chemother2008https://conductscience.org/library/papers/18326856PubMed
1924002092Isavuconazole pharmacodynamic target determination for Candida species in an in vivo murine disseminated candidiasis model.Antimicrob Agents Chemother2013https://conductscience.org/library/papers/24002092PubMed
2021357943Pharmacokinetics and pharmacodynamics of posaconazole for invasive pulmonary aspergillosis: clinical implications for antifungal therapy.J Infect Dis2011https://conductscience.org/library/papers/21357943PubMed

See all 65 referencesDownload CSV of references

Cited by44

The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 61 citations.

PMIDTitleJournalYearIn PapersSource
42394820
Exploratory model-based optimizing isavuconazole dosing regimens for Aspergillus spp. in adult patients according to serum albumin levels: a pharmacokinetic/pharmacodynamic analysis using Monte Carlo simulation.
Front Cell Infect Microbiol2026https://conductscience.org/library/papers/42394820PubMed
42212005Prospective study of pharmacokinetics of isavuconazole in critically ill patients undergoing continuous hemodialysis with and without acute-on-chronic liver failure.Ann Intensive Care2026https://conductscience.org/library/papers/42212005PubMed
42088097Characterization of isavuconazole pharmacokinetics and pharmacodynamics in a real-life cohort.JAC Antimicrob Resist2026https://conductscience.org/library/papers/42088097PubMed
42003963Isavuconazole in Pediatric Invasive Fungal Infections: Outcomes and Therapeutic Drug Monitoring in a Chinese Multicenter Case Series.Infect Drug Resist2026https://conductscience.org/library/papers/42003963PubMed
38935893Isavuconazole as prophylaxis and therapy for invasive fungal diseases: a real-life observational study.J Antimicrob Chemother2024https://conductscience.org/library/papers/38935893PubMed
38546795Pharmacokinetics of isavuconazole at different target sites in healthy volunteers after single and multiple intravenous infusions.J Antimicrob Chemother2024https://conductscience.org/library/papers/38546795PubMed
37971649Preclinical Pharmacokinetic/Pharmacodynamic Studies and Clinical Trials in the Drug Development Process of EMA-Approved Antifungal Agents: A Review.Clin Pharmacokinet2024https://conductscience.org/library/papers/37971649PubMed
37819504High Variability in Isavuconazole Unbound Fraction in Clinical Practice: A Call to Reconsider Pharmacokinetic/Pharmacodynamic Targets and Breakpoints.Clin Pharmacokinet2023https://conductscience.org/library/papers/37819504PubMed
37378040Therapeutic Drug Monitoring of Isavuconazole: Lessons Learnt from a Real-life Setting in a Tertiary Care Center in India.Indian J Crit Care Med2023https://conductscience.org/library/papers/37378040PubMed
36991227A Hybrid Algorithm Combining Population Pharmacokinetic and Machine Learning for Isavuconazole Exposure Prediction.Pharm Res2023https://conductscience.org/library/papers/36991227PubMed
36314941
In Vitro Susceptibilities of Worldwide Isolates of Intrapulmonary Aspergillus Species and Important Candida Species in Sterile Body Sites against Important Antifungals: Data from the Antimicrobial Testing Leadership and Surveillance Program, 2017-2020.
Microbiol Spectr2022https://conductscience.org/library/papers/36314941PubMed
35812838Antifungal Resistance and the Role of New Therapeutic Agents.Curr Infect Dis Rep2022https://conductscience.org/library/papers/35812838PubMed
35109772Resistance profiling of Aspergillus fumigatus to olorofim indicates absence of intrinsic resistance and unveils the molecular mechanisms of acquired olorofim resistance.Emerg Microbes Infect2022https://conductscience.org/library/papers/35109772PubMed
34959380
Population Pharmacokinetics and Pharmacodynamic Target Attainment of Isavuconazole against Aspergillus fumigatus and Aspergillus flavus in Adult Patients with Invasive Fungal Diseases: Should Therapeutic Drug Monitoring for Isavuconazole Be Considered as Mandatory as for the Other Mold-Active Azoles?
Pharmaceutics2021https://conductscience.org/library/papers/34959380PubMed
34035866Aspergillus fumigatus and aspergillosis: From basics to clinics.Stud Mycol2021https://conductscience.org/library/papers/34035866PubMed
33782009Efficacy and Associated Drug Exposures of Isavuconazole and Fluconazole in an Experimental Model of Coccidioidomycosis.Antimicrob Agents Chemother2021https://conductscience.org/library/papers/33782009PubMed
33396870Role and Interpretation of Antifungal Susceptibility Testing for the Management of Invasive Fungal Infections.J Fungi (Basel)2020https://conductscience.org/library/papers/33396870PubMed
32201545Extrapolating Antifungal Animal Data to Humans - Is it reliable?Curr Fungal Infect Rep2020https://conductscience.org/library/papers/32201545PubMed
31767725Population Pharmacokinetics of Intravenous Isavuconazole in Solid-Organ Transplant Recipients.Antimicrob Agents Chemother2020https://conductscience.org/library/papers/31767725PubMed
31717953RgsA Attenuates the PKA Signaling, Stress Response, and Virulence in the Human Opportunistic Pathogen Aspergillus fumigatus.Int J Mol Sci2019https://conductscience.org/library/papers/31717953PubMed

See all 44 cited byDownload CSV of cited by

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

None in this release

  • Grants
  • Trials
  • Comments and corrections
  • Genes
  • Drugs
  • Data

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/25753636

GET https://conductscience.org/api/papers/v1/25753636/references?page=2